Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 1, pp 21–23 | Cite as

Pre-exposure prophylaxis for HIV infection may be effective in older candidates, but proceed with caution

  • Adis Medical WritersEmail author
Disease Management
  • 78 Downloads

Abstract

The effectiveness and safety of tenofovir (TDF)-based therapy, which is the standard for pre-exposure prophylaxis (PrEP) for HIV infection, have not been specifically evaluated in older individuals. Major concerns relate to the older population being predisposed to kidney- and/or bone-related adverse events if they receive TDF-based PrEP. However, TDF-based PrEP may be a manageable treatment option in older candidates if careful screening, regular monitoring and appropriate sexual health education are also incorporated into the prevention plan.

Notes

Compliance with ethical standards

Conflict of interest

The article was adapted from Drugs & Aging 2018;35(6):485–91 [4] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

References

  1. 1.
    Tavoschi L, Gomes Dias J, Pharris A. New HIV diagnoses among adults aged 50 years or older in 31 European countries, 2004–15: an analysis of surveillance data. Lancet HIV. 2017;4(11):e514–21.CrossRefGoogle Scholar
  2. 2.
    Small LFF. What older adults know about HIV/AIDS: lessons from an HIV/AIDS education program. Educ Gerontol. 2009;36(1):26–45.CrossRefGoogle Scholar
  3. 3.
    Chen Y, Abraham Bussell S, Shen Z, et al. Declining inconsistent condom use but increasing HIV and syphilis prevalence among older male clients of female sex workers: analysis from sentinel surveillance sites (2010–2015), Guangxi, China. Medicine. 2016;95(22):e3726.CrossRefGoogle Scholar
  4. 4.
    Franconi I, Guaraldi G. Pre-exposure prophylaxis for HIV infection in the older patient: what can be recommended? Drugs Aging. 2018;35(6):485–91.CrossRefGoogle Scholar
  5. 5.
    Derdelinckx I, Wainberg MA, Lange JM, et al. Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med. 2006;3(11):e454.CrossRefGoogle Scholar
  6. 6.
    Fonsart J, Saragosti S, Taouk M, et al. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. J Antimicrob Chemother. 2017;72(2):478–85.CrossRefGoogle Scholar
  7. 7.
    McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51(8):937–46.CrossRefGoogle Scholar
  8. 8.
    Glidden DV, Mulligan K, McMahan V, et al. Brief report: recovery of bone mineral density after discontinuation of tenofovir-based HIV pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2017;76(2):177–82.CrossRefGoogle Scholar
  9. 9.
    Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(4):572–80.CrossRefGoogle Scholar
  10. 10.
    Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–31.CrossRefGoogle Scholar
  11. 11.
    Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62(1):e01710–7.Google Scholar
  12. 12.
    Wright E, Grulich A, Roy K, et al. Australasian Society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad. 2017;3(3):168–84.Google Scholar
  13. 13.
    Gandhi M, Glidden DV, Mayer K, et al. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV. 2016;3(11):e521–8.CrossRefGoogle Scholar
  14. 14.
    European AIDS Clinical Society. Guidelines for treatment of HIV-positive adults in Europe (version 9): 2017. http://www.eacsociety.org/. Accessed 13 Aug 2018.
  15. 15.
    Heidari S. Sexuality and older people: a neglected issue. Reprod Health Matters. 2016;24(48):1–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations